Regardless of the average increase in Hb level after therapy, which can be influenced by several factors (e.g., patient comorbidities, anemia severity, number of doses administered and trimester of pregnancy), there is substantial agreement that FCM is associated with higher Hb levels after therapy compared to other IV iron or oral formulations [11]. This evidence concerns the gene GSTM1 and anemia.